Homepage
Main navigation
Content area
Sitemap
Search
Direct navigation: news, legal matters, contact
News & Updates
Announcements
Swissmedic Journal
Medicines > Batch recalls
Medicines > Out-of-Stock
New on this website
Specification documents
Legal matters, standards
Legal matters
Legal Framework
Penal Law
Pharmacopoeia
Contact | Support & Help
General questions
Questions reg. medical devices
Media inquiries
Access to official documents
Feedback form
PDF invoice by e-mail
Support eGov services
Locations - situation plans
Myozyme™ 50 mg, Lyophilisat für ein Konzentrat zur Herstellung einer Infusionslösung (Alglucosidase alfa)
Languages
DE
FR
IT
EN
Service navigation
Contact
Media
Job vacancies
eGov portal (applications)
ElViS
Schweizerisches Heilmittelinstitut
Institut suisse des produits thérapeutiques
Istituto svizzero per gli agenti terapeutici
Swiss Agency for Therapeutic Products
Search
Main Navigation
Swissmedic
Latest News
Human medicines
Veterinary medicines
Complementary & herbal medicines
Medical devices
Services & lists
About us
Visible
Search
Latest News
Close
Human medicines
current page
Close
Veterinary medicines
Close
Complementary & herbal medicines
Close
Medical devices
Close
Services & lists
Close
About us
Close
Visible
Breadcrumb
Home
Human medicines
Authorisations
New authorisations
Myozyme™ 50 mg, Lyophilisat für ein Konzentrat zur Herstellung einer Infusionslösung (Alglucosidase alfa)
Unternavigation
Zurück
Zurück zu
Authorisations
New authorisations
Annual report
Context sidebar
Myozyme™ 50 mg, Lyophilisat für ein Konzentrat zur Herstellung einer Infusionslösung (Alglucosidase alfa)
Top of page
https://www.swissmedic.ch/content/swissmedic/en/home/humanarzneimittel/authorisations/new-medicines/myozyme_-50-mg--lyophilisat-fuer-ein-konzentrat-zur-herstellung-.html
